Clinical Trials Logo

Lennox-Gastaut Syndrome clinical trials

View clinical trials related to Lennox-Gastaut Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05626634 Active, not recruiting - Dravet Syndrome Clinical Trials

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Start date: November 8, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.

NCT ID: NCT05044819 Active, not recruiting - Dravet Syndrome Clinical Trials

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Start date: July 7, 2021
Phase: Phase 4
Study type: Interventional

This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.

NCT ID: NCT03936777 Active, not recruiting - Dravet Syndrome Clinical Trials

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Start date: April 22, 2019
Phase: Phase 3
Study type: Interventional

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

NCT ID: NCT03635073 Active, not recruiting - Epilepsy Clinical Trials

A Study of Soticlestat in Adults and Children With Rare Epilepsies

Endymion 1
Start date: July 19, 2018
Phase: Phase 2
Study type: Interventional

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.

NCT ID: NCT03355209 Active, not recruiting - Clinical trials for Lennox Gastaut Syndrome

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Start date: November 27, 2017
Phase: Phase 3
Study type: Interventional

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

NCT ID: NCT02655198 Active, not recruiting - Epilepsy Clinical Trials

Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy

FFA-LGS
Start date: January 2016
Phase: Phase 2
Study type: Interventional

In this trial, the potential anti-epileptic effect of low dose fenfluramine in Lennox Gastaut epilepsy will be studied. An exploratory dose finding add-on trial is proposed. At baseline and at the end of the study, ECG and ultrasound of the heart will be performed as part of the safety follow up.